Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 20%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is expecting a positive uptick in sentiment for the potential approval of Zanzalintinib plus Atezolizumab (Tecentriq) in patients with non-microsatellite instability-high colorectal cancer on December 3, 2026, in addition to multiple upcoming catalysts in ongoing trials for other indications. The company has shown strong growth in end-user demand for its lead product Cabometyx, and its stock buyback program and disciplined control of expenses also provide potential for earnings uptick in the future. The company's financials are strong, with a DCF-based firm value of approximately $13.9B and a 12-month price objective of $56 per share, based on a 15x multiple on the estimated FY26 non-GAAP EPS of $3.66. The company's partnerships and pipeline expansion also offer potential for future growth and re-rating of the stock.

Bears say

Exelixis is currently facing numerous risks in the biotechnology sector, including commercial risks with Cabometyx sales being hindered by the introduction of competitors' products, the possibility of unfavorable data from ongoing clinical programs, and the potential for generic erosion of their existing blockbuster drug, cabozantinib. Additionally, their reliance on external funding for their research and development could create challenges in the capital-raising environment. However, Exelixis's strong cash flow and aggressive buyback program may provide support for their stock in the short term.

Exelixis (EXEL) has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 20% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 15 analysts, Exelixis (EXEL) has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.